FDA Declares End to Ozempic and Wegovy Shortages After Two Years
The FDA announces the resolution of the prolonged shortages of Ozempic and Wegovy, allowing Novo Nordisk to meet U.S. demand for these treatments.
Overview
The FDA has declared the shortages of popular diabetes and weight loss drugs Ozempic and Wegovy resolved, enabling Novo Nordisk to meet current and future demand. Despite this, intermittent supply disruptions may occur during the distribution process. The resolution comes after Novo Nordisk invested $6.5 billion in production capacity in the U.S. Since 2022, compounded versions of these medications had provided alternative access, raising concerns as their production may become limited with the official end of the shortage. The ongoing market dynamics may impact competitors in the burgeoning weight loss drug industry.
Content generated by AI—learn more or report issue.
Get both sides in 5 minutes with our daily newsletter.
Analysis
Analysis unavailable for this viewpoint.
Articles (4)
No highlight available for this article.
USA TODAY·4M·No highlight available for this article.
CBS News·4M·No highlight available for this article.
Associated Press·4M·No highlight available for this article.
CNBC·4M·FAQ
The resolution of the shortages was primarily due to Novo Nordisk's substantial efforts to increase manufacturing capacity, including a $6.5 billion investment in U.S. production facilities. This allowed them to meet or exceed current and projected U.S. demand for these medications.
The end of the shortages could impact companies like Hims & Hers, which have been producing compounded versions under FDA rules allowing mass production when the originals are hard to obtain. The FDA has stated it will not take action against these compounders for a limited time to avoid disrupting patient treatment.
Although the shortages are resolved, there may still be intermittent and limited localized supply disruptions as products move through the supply chain.
History
- This story does not have any previous versions.